

Tetanus Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/TC8A10F78643EN.html>

Date: May 2024

Pages: 140

Price: US\$ 6,499.00 (Single User License)

ID: TC8A10F78643EN

Abstracts

The 7 major tetanus markets reached a value of US\$ 1.1 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 1.6 Billion by 2034, exhibiting a growth rate (CAGR) of 3.46% during 2024-2034.

The tetanus market has been comprehensively analyzed in IMARC's new report titled "Tetanus Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Tetanus, also known as lockjaw, refers to a serious bacterial infection caused by the bacterium *Clostridium tetani*. The bacteria can enter the body through a wound or a cut, and they release a potent toxin that affects the muscles and nerves. The muscles most commonly afflicted are those in the jaw, which can cause difficulty opening the mouth and swallowing. However, the infection can spread to various other parts of the body, causing muscle stiffness and spasms throughout. Some individuals suffering from the disease may also experience a fever, often accompanied by sweating. The diagnosis of tetanus typically relies on a combination of the patient's clinical symptoms, medical history, and laboratory tests. If there is an open wound, a sample might be taken to culture it and identify the presence of bacteria. The healthcare provider may also perform a complete blood count to evaluate any signs of infection or abnormalities in the blood cells. In some cases, electromyography may be further conducted to determine the electrical activity in muscles. This test can help to confirm the presence of muscle spasms and identify the characteristic pattern associated with the condition.

The increasing cases of deep puncture wounds, burns, crush injuries, etc., which provide a suitable breeding ground for the bacteria to multiply, are primarily driving the tetanus market. In addition to this, the rising prevalence of inadequate immunization

against the illness that enhances the risk of contracting the infection is also creating a positive outlook for the market. Moreover, the widespread adoption of intravenous antibiotics, such as penicillin, metronidazole, doxycycline, etc., to kill bacteria and prevent the release of hazardous chemicals in patients is further bolstering the market growth. Apart from this, the emerging popularity of neuromuscular blockers, since they work by blocking the transmission of nerve impulses at the myoneural junction to alleviate the severe muscle spasms and rigidity associated with the condition, is acting as another significant growth-inducing factor. Additionally, the inflating demand for tetanus immune globulin (TIG) therapy to neutralize the bacterial toxin and prevent its harmful effects by providing immediate passive immunity against the pathogen is expected to drive the tetanus market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the tetanus market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for tetanus and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the tetanus market in any manner.

Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

Countries Covered

United States

Germany

France

United Kingdom

Italy

Spain

Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario

Historical, current, and future performance of the tetanus market

Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the tetanus market

Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current tetanus marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

How has the tetanus market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the tetanus market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the tetanus market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (?2018-2034?) of tetanus across the seven major markets?

What is the number of prevalent cases (?2018-2034?) of tetanus by age across the seven major markets?

What is the number of prevalent cases (?2018-2034?) of tetanus by gender across the seven major markets?

How many patients are diagnosed (?2018-2034?) with tetanus across the seven major markets?

What is the size of the tetanus patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of tetanus?

What will be the growth rate of patients across the seven major markets?

Tetanus: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for tetanus drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the tetanus market?

What are the key regulatory events related to the tetanus market?

What is the structure of clinical trial landscape by status related to the tetanus market?

What is the structure of clinical trial landscape by phase related to the tetanus market?
What is the structure of clinical trial landscape by route of administration related to the tetanus market?

Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 TETANUS - INTRODUCTION

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

5 TETANUS - DISEASE OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

6 PATIENT JOURNEY

7 TETANUS - EPIDEMIOLOGY AND PATIENT POPULATION

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
 - 7.2.1 Epidemiology Scenario (2018-2023)
 - 7.2.2 Epidemiology Forecast (2024-2034)
 - 7.2.3 Epidemiology by Age (?2018-2034?)
 - 7.2.4 Epidemiology by Gender (?2018-2034?)
 - 7.2.5 Diagnosed Cases (?2018-2034?)
 - 7.2.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.3 Epidemiology Scenario - United States
 - 7.3.1 Epidemiology Scenario (2018-2023)
 - 7.3.2 Epidemiology Forecast (2024-2034)
 - 7.3.3 Epidemiology by Age (?2018-2034?)
 - 7.3.4 Epidemiology by Gender (?2018-2034?)
 - 7.3.5 Diagnosed Cases (?2018-2034?)
 - 7.3.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.4 Epidemiology Scenario - Germany
 - 7.4.1 Epidemiology Scenario (2018-2023)
 - 7.4.2 Epidemiology Forecast (2024-2034)
 - 7.4.3 Epidemiology by Age (?2018-2034?)
 - 7.4.4 Epidemiology by Gender (?2018-2034?)
 - 7.4.5 Diagnosed Cases (?2018-2034?)
 - 7.4.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.5 Epidemiology Scenario - France
 - 7.5.1 Epidemiology Scenario (2018-2023)
 - 7.5.2 Epidemiology Forecast (2024-2034)
 - 7.5.3 Epidemiology by Age (?2018-2034?)
 - 7.5.4 Epidemiology by Gender (?2018-2034?)
 - 7.5.5 Diagnosed Cases (?2018-2034?)
 - 7.5.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.6 Epidemiology Scenario - United Kingdom
 - 7.6.1 Epidemiology Scenario (2018-2023)
 - 7.6.2 Epidemiology Forecast (2024-2034)
 - 7.6.3 Epidemiology by Age (?2018-2034?)
 - 7.6.4 Epidemiology by Gender (?2018-2034?)
 - 7.6.5 Diagnosed Cases (?2018-2034?)
 - 7.6.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.7 Epidemiology Scenario - Italy
 - 7.7.1 Epidemiology Scenario (2018-2023)
 - 7.7.2 Epidemiology Forecast (2024-2034)
 - 7.7.3 Epidemiology by Age (?2018-2034?)

- 7.7.4 Epidemiology by Gender (?2018-2034?)
- 7.7.5 Diagnosed Cases (?2018-2034?)
- 7.7.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.8 Epidemiology Scenario - Spain
 - 7.8.1 Epidemiology Scenario (2018-2023)
 - 7.8.2 Epidemiology Forecast (2024-2034)
 - 7.8.3 Epidemiology by Age (?2018-2034?)
 - 7.8.4 Epidemiology by Gender (?2018-2034?)
 - 7.8.5 Diagnosed Cases (?2018-2034?)
 - 7.8.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.9 Epidemiology Scenario - Japan
 - 7.9.1 Epidemiology Scenario (2018-2023)
 - 7.9.2 Epidemiology Forecast (2024-2034)
 - 7.9.3 Epidemiology by Age (?2018-2034?)
 - 7.9.4 Epidemiology by Gender (?2018-2034?)
 - 7.9.5 Diagnosed Cases (?2018-2034?)
 - 7.9.6 Patient Pool/Treated Cases (?2018-2034?)

8 TETANUS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

9 TETANUS - UNMET NEEDS

10 TETANUS - KEY ENDPOINTS OF TREATMENT

11 TETANUS - MARKETED PRODUCTS

- 11.1 List of Tetanus Marketed Drugs Across the Top 7 Markets
 - 11.1.1 Adacel (DTaP vaccine) - Sanofi
 - 11.1.1.1 Drug Overview
 - 11.1.1.2 Mechanism of Action
 - 11.1.1.3 Regulatory Status
 - 11.1.1.4 Clinical Trial Results
 - 11.1.1.5 Sales Across Major Markets
 - 11.1.2 Boostrix (DTaP vaccine adult) - GlaxoSmithKline
 - 11.1.2.1 Drug Overview

- 11.1.2.2 Mechanism of Action
- 11.1.2.3 Regulatory Status
- 11.1.2.4 Clinical Trial Results
- 11.1.2.5 Sales Across Major Markets
- 11.1.3 Daptacel (DTaP vaccine paediatric Tripacel) - Sanofi
 - 11.1.3.1 Drug Overview
 - 11.1.3.2 Mechanism of Action
 - 11.1.3.3 Regulatory Status
 - 11.1.3.4 Clinical Trial Results
 - 11.1.3.5 Sales Across Major Markets
- 11.1.4 Kinrix (DTaP-poliovirus vaccine paediatric) - GlaxoSmithKline
 - 11.1.4.1 Drug Overview
 - 11.1.4.2 Mechanism of Action
 - 11.1.4.3 Regulatory Status
 - 11.1.4.4 Clinical Trial Results
 - 11.1.4.5 Sales Across Major Markets
- 11.1.5 Tenivac (Tetanus and Diphtheria Toxoids Adsorbed) - Sanofi
 - 11.1.5.1 Drug Overview
 - 11.1.5.2 Mechanism of Action
 - 11.1.5.3 Regulatory Status
 - 11.1.5.4 Clinical Trial Results
 - 11.1.5.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 TETANUS - PIPELINE DRUGS

- 12.1 List of Tetanus Pipeline Drugs Across the Top 7 Markets
 - 12.1.1 Drug Name – Company Name
 - 12.1.1.1 Drug Overview
 - 12.1.1.2 Mechanism of Action
 - 12.1.1.3 Clinical Trial Results
 - 12.1.1.4 Safety and Efficacy
 - 12.1.1.5 Regulatory Status

Kindly note that the complete list of pipeline drugs has been provided in the report.

13. TETANUS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14. TETANUS – CLINICAL TRIAL LANDSCAPE

- 14.1 Drugs by Status
- 14.2 Drugs by Phase
- 14.3 Drugs by Route of Administration
- 14.4 Key Regulatory Events

15 TETANUS - MARKET SCENARIO

- 15.1 Market Scenario - Key Insights
- 15.2 Market Scenario - Top 7 Markets
 - 15.2.1 Tetanus - Market Size
 - 15.2.1.1 Market Size (2018-2023)
 - 15.2.1.2 Market Forecast (2024-2034)
 - 15.2.2 Tetanus - Market Size by Therapies
 - 15.2.2.1 Market Size by Therapies (2018-2023)
 - 15.2.2.2 Market Forecast by Therapies (2024-2034)
- 15.3 Market Scenario - United States
 - 15.3.1 Tetanus - Market Size
 - 15.3.1.1 Market Size (2018-2023)
 - 15.3.1.2 Market Forecast (2024-2034)
 - 15.3.2 Tetanus - Market Size by Therapies
 - 15.3.2.1 Market Size by Therapies (2018-2023)
 - 15.3.2.2 Market Forecast by Therapies (2024-2034)
 - 15.3.3 Tetanus - Access and Reimbursement Overview
- 15.4 Market Scenario - Germany
 - 15.4.1 Tetanus - Market Size
 - 15.4.1.1 Market Size (2018-2023)
 - 15.4.1.2 Market Forecast (2024-2034)
 - 15.4.2 Tetanus - Market Size by Therapies
 - 15.4.2.1 Market Size by Therapies (2018-2023)
 - 15.4.2.2 Market Forecast by Therapies (2024-2034)
 - 15.4.3 Tetanus - Access and Reimbursement Overview
- 15.5 Market Scenario - France
 - 15.5.1 Tetanus - Market Size
 - 15.5.1.1 Market Size (2018-2023)
 - 15.5.1.2 Market Forecast (2024-2034)
 - 15.5.2 Tetanus - Market Size by Therapies
 - 15.5.2.1 Market Size by Therapies (2018-2023)

- 15.5.2.2 Market Forecast by Therapies (2024-2034)
- 15.5.3 Tetanus - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
 - 15.6.1 Tetanus - Market Size
 - 15.6.1.1 Market Size (2018-2023)
 - 15.6.1.2 Market Forecast (2024-2034)
 - 15.6.2 Tetanus - Market Size by Therapies
 - 15.6.2.1 Market Size by Therapies (2018-2023)
 - 15.6.2.2 Market Forecast by Therapies (2024-2034)
 - 15.6.3 Tetanus - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
 - 15.7.1 Tetanus - Market Size
 - 15.7.1.1 Market Size (2018-2023)
 - 15.7.1.2 Market Forecast (2024-2034)
 - 15.7.2 Tetanus - Market Size by Therapies
 - 15.7.2.1 Market Size by Therapies (2018-2023)
 - 15.7.2.2 Market Forecast by Therapies (2024-2034)
 - 15.7.3 Tetanus - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
 - 15.8.1 Tetanus - Market Size
 - 15.8.1.1 Market Size (2018-2023)
 - 15.8.1.2 Market Forecast (2024-2034)
 - 15.8.2 Tetanus - Market Size by Therapies
 - 15.8.2.1 Market Size by Therapies (2018-2023)
 - 15.8.2.2 Market Forecast by Therapies (2024-2034)
 - 15.8.3 Tetanus - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
 - 15.9.1 Tetanus - Market Size
 - 15.9.1.1 Market Size (2018-2023)
 - 15.9.1.2 Market Forecast (2024-2034)
 - 15.9.2 Tetanus - Market Size by Therapies
 - 15.9.2.1 Market Size by Therapies (2018-2023)
 - 15.9.2.2 Market Forecast by Therapies (2024-2034)
 - 15.9.3 Tetanus - Access and Reimbursement Overview

16 TETANUS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

17 TETANUS MARKET - SWOT ANALYSIS

17.1 Strengths

17.2 Weaknesses

17.3 Opportunities

17.4 Threats

18 TETANUS MARKET – STRATEGIC RECOMMENDATIONS

19 APPENDIX

I would like to order

Product name: Tetanus Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/TC8A10F78643EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/TC8A10F78643EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

